Innovative Breakthrough: BioRestorative Therapies Secures Key Patent for Obesity Treatment Program
BioRestorative Therapies, Inc., a pioneering clinical-stage company specializing in stem cell-based therapies, has achieved a significant milestone in its quest to combat obesity and metabolic disorders. The United States Patent and Trademark Office has issued a notice of allowance for a patent application related to the company’s ThermoStem® program. This development, announced on December 12, […]
BioRestorative Therapies Activates Northwell Health for Phase 2 Clinical Trial on Chronic Lumbar Disc Disease
BioRestorative Therapies, Inc., a clinical-stage company specializing in stem cell-based therapies, has announced the activation of Northwell Health, the largest healthcare provider in New York State, for its ongoing Phase 2 clinical trial targeting chronic lumbar disc disease (cLDD). This activation permits patients in New York to participate in the BRTX-100 trial. The collaboration between […]
BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication
MELVILLE, N.Y., Dec. 06, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has been awarded a Small Business Innovation Research (SBIR) Phase I grant from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the […]
BioRestorative Therapies to Participate in the Roth Inaugural Healthcare Opportunities Conference
MELVILLE, NY., Sept. 27, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will be participating in the Roth Inaugural Healthcare Opportunities Conference being held at The Yale Club in New York City on October 6, 2022. […]
BioRestorative Therapies Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
MELVILLE, N.Y.,, April 18, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has selected 10 of its 15 clinical sites for its Phase 2 clinical trial targeting chronic lumbar disc disease. BioRestorative’s Phase 2 trial is a […]